January 2016

In This Issue
- WIPO Re:Search Statistics
- Cornerstones of Collaboration
- New Member Announcement
- Funding Announcement
- Member Spotlight
- Highlighted Contributions
- Members In the News
- Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

Happy New Year! I hope you had a chance to read through the many WIPO Re:Search collaborations featured in BVGH’s recent publication, *Accelerating R&D for Neglected Diseases through Global Collaborations: WIPO Re:Search Partnership Stories 2013-2015*. Feedback on the storybook has been extremely positive. BVGH is now busy preparing the 2015 *Partnership Hub Annual Report*, which will be shared with you over the coming weeks.

The next couple of months are already shaping up to be full of new and exciting partnering opportunities for our WIPO Re:Search Members. In order to manage the growing number of WIPO Re:Search collaborations effectively, BVGH is implementing some new processes and documentation. Our intent is to set collaboration expectations across our Members and streamline our partnering and project management. We look forward to your feedback as we share the documentation and implement our new processes.

I am pleased to welcome our newest Member, the Institut Pasteur.

Ujwal Sheth will be representing BVGH and featuring WIPO Re:Search in her presentation at the AnthelMintics: From Discovery to Resistance II conference in San Diego next month. Please plan to meet with Ujwal if you will be attending.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.
**Special Announcement**

Ujwal Sheth will be representing BVGH and presenting WIPO Re:Search at the Anthelmintics: From Discovery to Resistance II conference in San Diego this February. If you will be attending this meeting and would like to schedule a time to speak, please send Ujwal an email.

---

**WIPO Re:Search Statistics**

![Agreements: 99 | Members: 101](image)

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

---

**Cornerstones of Collaboration**

Eisai has agreed to provide the University of California, San Diego (UCSD), with phosphodiesterase V (PDEV) inhibitors to screen against Leishmania, T. cruzi, S. mansoni, and Brugia.
Elsai has agreed to expand its collaboration with Prof. Alister Craig, Dean of Biological Sciences, Liverpool School of Tropical Medicine (LSTM), by sharing additional compounds – including PAR1 inhibitors that are active in animal coagulation models – that Alister will use to further study the role of PAR1 in the pathology of cerebral malaria.

---

**New Member Announcement**

We are pleased to announce that **Institut Pasteur** has joined WIPO Re:Search.

Founded by the renowned Louis Pasteur in 1888, the Institut Pasteur is recognized as the birthplace of microbiology. Researchers at the Institut Pasteur focus on the molecular basis of *Leishmania* virulence, host-*Plasmodium* interactions, pathogenicity of mycobacteria, and translational rabies research, among many others.

---

**BVGH FundFinder Featured Funding Announcement**

**Tropical Medicine Research Centers**

The purpose of this opportunity is to solicit applications from institutions/organizations that propose to conduct research on the causes, diagnosis, prevention, and treatment of tropical diseases in endemic areas. The scope of the research to be supported is limited to select neglected tropical diseases (NTDs) and their corresponding vectors. Research may be focused on a single pathogen or more than one pathogen causing NTDs. Multi-disciplinary research and/or study of multiple pathogens is encouraged. This program is not intended to support research that can be conducted primarily in US institutions.

**Funding amount**: $500,000 maximum/year for up to five years  
**Funder**: US National Institutes of Health (NIH)  
**Deadline**: Letter of intent due May 3, 2016  
**Eligibility**: Applicant organizations must be headquartered in foreign (non-US) resource-constrained countries.

For more information about BVGH FundFinder, please email [Roopa Sriram](mailto:roopa.sriram@bvgh.org).

---

**Member Spotlight**

**McGill University** is currently accepting applications for its **McGill Summer Institute in Infectious Diseases and Global Health**. This year the McGill Summer Institute is offering five, one-week courses: Tuberculosis Research Methods, Global Health Diagnostics, Tropical and Parasitic Diseases, Molecular and Genetic Epidemiology, and Advanced Tuberculosis Diagnostics Research. These courses are taught by internationally-recognized faculty and offer participants the opportunity to learn while networking with fellow global health professionals and policy-makers from disease endemic countries. Click [here](http://mcsiglobal.ca/) to download the course brochure. **Applications are due February 7, 2016.** Apply now at [http://mcsiglobal.ca/](http://mcsiglobal.ca/)
Highlighted Contributions

Featured this month is one contribution submitted by Northeastern University to the WIPO Re:Search Database.

Drug discovery capabilities for neglected tropical diseases (ID: 2043)
Northeastern University scientists are willing to provide their collaborative research capabilities in hit-to-lead and lead optimization medicinal chemistry for protozoan diseases and other neglected tropical diseases. The researchers have established internal programs and are looking for collaborators who wish to share early chemistry data to initiate optimization programs.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.

WIPO Re:Search Members In the News

Last December, the Merck KGaA, Darmstadt, Germany Executive Board traveled to Africa where they met with Ministers of Health, University professors, and patient groups. Click here to watch a video about the Board’s visit and Merck KGaA’s Africa plans.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb. 9-12</td>
<td>Anthelmintics: From Discovery to Resistance II</td>
<td>San Diego, California</td>
<td>Website</td>
</tr>
<tr>
<td>Feb. 28-Mar. 3</td>
<td>Keystone Symposium: Tuberculosis Co-Morbidity and Immunopathogenesis</td>
<td>Keystone, Colorado</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 2-5</td>
<td>17th International Congress on Infectious Diseases</td>
<td>Hyderabad, India</td>
<td>Website</td>
</tr>
</tbody>
</table>
February 2016

In This Issue

WIPO Re:Search Statistics
Cornerstones of Collaboration
New Member Announcement
Partnership Hub Central
Funding Announcement
Member Spotlight
Highlighted Contributions
WIPO Re:Search in the News
Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

You should have received my letter yesterday with a link to BVGH’s 2015 Partnership Hub Annual Report. If you would like a hard copy of the report, please reach out to Jasmine Clark and we will get one or more in the mail to you.

Last week theBVGH team took advantage of GlaxoSmithKline (GSK) and University of South Florida (USF) scientists’ visits to Seattle to meet and discuss collaboration interests. If you or your colleagues come to Seattle, please let us know. We would be pleased to welcome you to our office to discuss your research and partnering needs.

In order to manage the growing number of WIPO Re:Search collaborations effectively, BVGH is implementing new partnering processes. Chief among these processes is the development of key documentation including a set of collaboration guidelines and collaboration outline and close-out form that Members are requested to complete prior to and after their collaboration has been established, respectively. We invite all Members to review the documents and provide feedback.

I am pleased to welcome our newest Member, Malaria Consortium, to WIPO Re:Search.

As always, please forward this Snapshot to your colleagues.
and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

---

Special Announcement

The 2015 BVGH Partnership Hub Annual Report is now available. Click [here](#) to download a copy of the report.

WIPO Re:Search Statistics

![Agreements and Members](#)

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

Collaborations by Current Stage of Development

- **Basic Research/Discovery**: 37
- **Screening for Repurposing**: 25
- **HIT ID**: 17
- **Hit to Lead**: 8
- **Preclinical Development**: 11
- **Clinical Development**: 1

---

Cornerstones of Collaboration
Building on their prior relationship established through WIPO Re:Search, Prof. Alexander Odaibo, Head, Parasitology Research Unit, Department of Zoology, Faculty of Science, University of Ibadan, will collaborate with Prof. Wei Hu, Head, Joint Laboratory of Genetics and Ecology of Parasite-Vector, National Institute of Parasitic Diseases (NIPD), Chinese CDC/Fudan University, to work on serum samples from Nigerian schistosomiasis patients. The aim of the collaboration is to identify potential Schistosoma mansoni and S. haematobium antigens to incorporate into a schistosomiasis rapid diagnostic. Prof. Hu will also host a University of Ibadan post-doctoral scientist during this project.

Merck KGaA, Darmstadt, Germany will provide Dr. Fidelis Cho-Ngwa, Associate Professor, University of Buea, with a subset of highly potent Hsp90 inhibitors to screen against Onchocerca worms, and identify compounds that selectively kill both microfilariae and adult O. volvulus, without adverse effects to Loa loa microfilariae.

**New Member Announcement**

We are pleased to announce that Malaria Consortium has joined WIPO Re:Search.

Malaria Consortium, headquatered in London, UK, was established in 2003 to develop sustainable, evidence-based programs to combat malaria and other communicable diseases. In addition to providing technical and operational support for national malaria control programs, Malaria Consortium analyzes and implements innovative solutions and technologies to identify malaria cases. Malaria Consortium also focuses its efforts on disease mapping, community drug delivery, and design and implementation of national control programs for dengue fever, lymphatic filariasis, schistosomiasis, trachoma, and soil-transmitted helminthiases.

**Partnership Hub Central**

Dr. Minelik Alemu Getaahun, Assistant Director General for Global Issues, WIPO, co-hosted with Egyptian Ambassador H.E. Amr Ramadan a briefing for 19 Ambassadors and Deputy Chiefs of Mission from Africa. The briefing highlighted WIPO Re:Search’s progress since its launch, the number of African Members, and the financial support for research sabbaticals for scientists from the African continent. This briefing will be repeated later in the year for country representatives who could not attend, and represents part of WIPO’s targeted outreach to the Geneva policy community.

**BVGH FundFinder Featured Funding Announcement**

IZUMI Foundation Grants

The IZUMI Foundation looks for organizations with promising and practical innovations that improve the health outcomes for people living in the most impoverished areas of Africa, Latin America, and the Caribbean. Funded research programs must fall within one of five program areas: infectious diseases, neglected tropical diseases, malnutrition, maternal & neonatal health, and healthcare infrastructure.
Funding amount: Typically $45,000 - $100,000 over two years  
Funder: IZUMI Foundation  
Deadline: Ongoing, but letters of inquiry are accepted during April, May, and June  
Eligibility: Organizations within the United States must have IRS designated tax-exempt status to be eligible to apply to the Foundation; organizations outside of the United States must have legally-recognized non-profit status to be eligible to apply to the Foundation.

For more information about BVGH FundFinder, please email Roopa Sriram.

---

**Member Spotlight**

Researchers at the Center for Discovery and Innovation in Parasitic Diseases, University of California, San Diego (UCSD) and GlaxoSmithKline (GSK)* recently published the results of their WIPO Re:Search collaboration. Through this collaboration, the researchers used GSK’s Published Kinase Inhibitor Set 1 (PKIS1) and Set 2 (PKIS2) to investigate the Schistosoma mansoni polo-like kinase 1 (SmPLK1) as a possible drug target. Click here to read the paper.

*The team of GSK scientists that developed PKIS1 and PKIS2 recently moved to the University of North Carolina (UNC) Chapel Hill. GSK licensed PKIS1 and PKIS2 to UNC Chapel Hill. Interested parties can reach out to the UNC scientists with questions about the kinase inhibitor sets (sgc-unc@unc.edu).

---

**Highlighted Contributions**

Featured this month is a contribution submitted by Medicines for Malaria Venture (MMV) to the WIPO Re:Search Database.

**New, cheaper production process for mefloquine hydrochloride (ID: 2001)**

A new method for synthesizing mefloquine hydrochloride has been developed. This new method can reduce production costs of antimalarial drugs that include mefloquine, such as artemunate-mefloquine (ASMQ).

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.
WIPO Re:Search In the News

WIPO Wire published an announcement of the Institut Pasteur’s new membership in WIPO Re:Search.

Tom Bombelles, Head, Global Health, WIPO, referenced WIPO Re:Search in his remarks on IP, innovation, and global health at the UN High-Level Panel on Access to Medicines. Click here to read more.

Experts at the briefing (left to right): Lynn Gentile, Tom Bombelles, Antony Taubman, and Christoph Spennemann

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb. 28 –</td>
<td>Keystone Symposium: Tuberculosis Co-Morbidities and Immunopathogenesis</td>
<td>Keystone, Colorado</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mar. 2-5</td>
<td>17th International Congress on Infectious Diseases (ICID)</td>
<td>Hyderabad, India</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 29-31</td>
<td>World Vaccine Congress 2016</td>
<td>Washington, DC</td>
<td>Website</td>
</tr>
</tbody>
</table>
Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

BVGH established the 100th WIPO Re:Search collaboration last month! This is an important milestone for WIPO Re:Search. It’s only been four years since the Consortium was launched, but as evidenced by the number of collaborations – and more importantly the number of advancing collaborations – WIPO Re:Search is having an impact.

Seventy percent of WIPO Re:Search User and Provider Members have participated in a collaboration. If you have not yet been engaged in a WIPO Re:Search partnership, please reach out to Ujwal Sheth to schedule a call to discuss your research interests and needs. We look forward to identifying innovative projects that leverage your assets and expertise to advance neglected infectious disease product development.

I will be participating in the United Nations Secretary-General’s High-Level Panel on Access to Medicines in London this week. The objective of the Panel’s discussion is to propose incremental modifications to existing pharmaceutical innovation and access models. I look forward to seeing some of you in London.

I am pleased to welcome our newest Member, the Research Institute for Tropical Medicine (RITM), to WIPO Re:Search.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.
WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here].

Click [here] to view a complete list of WIPO Re:Search Members.
Cornerstones of Collaboration

Dr. David Griggs, Director of Cellular and Molecular Biology, and Dr. Marv Meyers, Director of Medicinal Chemistry, Center for World Health & Medicine (CWHM), recently published the results of their WIPO Re:Search collaboration with Pfizer and Sanofi. Through this collaboration, David, Marv, and colleagues at Saint Louis University and PATH assessed Pfizer and Sanofi neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea. Click here to read the paper.

New Member Announcement

We are pleased to announce that the Research Institute for Tropical Medicine (RITM) has joined WIPO Re:Search.

The Research Institute for Tropical Medicine, based in Manila, Philippines, was established in 1981 to plan and implement research programs for tropical infectious diseases. Research areas of interest at RITM include schistosomiasis vaccine development, lymphatic filariasis and leprosy diagnostic development, dengue fever clinical studies, and rabies vaccinology.

Partnership Hub Central

Ujwal Sheth, BVGH, gave a presentation on accelerating anthelmintic discovery through WIPO Re:Search at the Anthelmintics: From Discovery to Resistance II conference in San Diego.

Dr. Thavy Long, a postdoctoral fellow at the University of California, San Diego (UCSD), presented the results of her WIPO Re:Search collaboration with GlaxoSmithKline (GSK). These results were recently published in PLoS NTDs.
While in San Diego, Ujwal met with researchers at the University of California, San Diego (UCSD) including Dr. Jim McKerrow, Dean, and Dr. Conor Caffrey, Associate Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences. During the visit, Jim gave Ujwal a tour of the Center for Discovery and Innovation in Parasitic Diseases (CDIPD) parasitology and high-throughput screening (HTS) facilities.

---

**BVGH FundFinder Featured Funding Announcement**

**MMV 14th Call for Proposals**
Medicines for Malaria Venture (MMV) has open calls for proposals in the first quarter of each year. This year MMV is currently welcoming research proposals in three areas that it has highlighted as necessary for the control and eradication of malaria. These key areas are: compounds addressing the key priorities of the malaria eradication agenda; asexual liver and blood stage antimalarial compounds; and novel approaches for antimalarial compound screens.

**Funding amount:** Not specified  
**Funder:** Medicines for Malaria Venture (MMV)  
**Deadline:** March 25th, 2016  
**Eligibility:** Not specified

For more information about BVGH FundFinder, please email Roopa Sriram.

---

**Member Spotlight**

Oussama Ben Fadhel, Project Manager in Technology Transfer, Institut Pasteur de Tunis, was selected to participate in the Association of University Technology Managers (AUTM) 2016 Annual Meeting,
which was held last month in San Diego.

“I think it was one of the better meetings that I’ve had with these masses of professionals. I was able to exchange with different people with a broad range of expertise and experiences. Whether via social media or in person, building relationships is a long-term process. The AUTM meeting was an excellent opportunity to strengthen my network one person at a time.” - Oussama Ben Fadhel

Oussama Ben Fadhel (left) and Stephen Gardner, Chief Counsel, Commercial Law Development Program (CLDP) (right). CLDP sponsored Oussama’s participation at the AUTM 2016 Annual Meeting.

---

**Highlighted Contributions**

Featured this month are two contributions submitted by the National Institutes of Health (NIH) to the [WIPO Re:Search Database](https://www.wipo.int/research/en/).

**Dimeric Naphthylisoquinoline Alkaloids and Synthesis Methods Thereof (ID: 628)**
The present invention provides methods of preparing dimeric naphthylisoquinoline alkaloids. Two monomeric naphthylisoquinoline alkaloids can be coupled together to form homodimers or heterodimers. Monomers may possess a C-8' to C-5 naphthalene/isoquinoline linkage. The present invention also provides new, medically useful homodimeric and heterodimeric naphthylisoquinoline compounds and derivatives thereof.

**Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof (#1) (ID: 746)**
*Leishmania* parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly bites.
Sand fly saliva is known to enhance *Leishmania* infection, while immunity to the saliva protects against infection. This invention claims nine major salivary proteins from the sand fly vector of *L. major*, *Phlebotomus papatasi*, nucleic acids encoding the proteins, vaccines comprising the proteins and/or nucleic acids, and methods of producing an immune response to prevent leishmaniasis.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.

---

**WIPO Re:Search In the News**

Dr. Dennis Liotta, Executive Director, Emory Institute for Drug Development, *Emory University*, mentioned WIPO Re:Search during his presentation at TEDxPlaceDesNations: “Transforming Lives” event. Click [here](#) to watch his talk.

![Dennis Liotta](image)

Dennis Liotta described a drug discoverer's approach to neglected diseases

---

**Upcoming Global Health Events**

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar. 29-31</td>
<td>World Vaccine Congress 2016</td>
<td>Washington, DC</td>
<td><a href="#">Website</a></td>
</tr>
<tr>
<td>May 1-5</td>
<td>Keystone Symposium: Positive-Strand RNA Viruses</td>
<td>Austin, TX</td>
<td><a href="#">Website</a></td>
</tr>
<tr>
<td>May 22-26</td>
<td>Keystone Symposium: New Approaches to Vaccines for Human and Veterinary Tropical Diseases</td>
<td>Cape Town, South Africa</td>
<td><a href="#">Website</a></td>
</tr>
</tbody>
</table>
Dear WIPO Re:Search Members and Friends,

Intellectual property has been in the spotlight over the past couple of months. The United Nations Secretary General’s High-Level Panel on Access to Medicines held an event and hearing in London, which BVGH was invited to participate in. WIPO hosted a workshop on regional IP management in the Philippines and published the results of last year’s global patent filings. Last week WIPO convened a landmark conference on IP and development in Geneva. WIPO Director General Francis Gurry opened the meeting noting that, “The position of IP in the economy is no longer at the periphery of economic systems; it is very much central to the economic systems we see now.”

The use of intellectual property as a means to accelerate and stimulate health innovations is core to WIPO Re:Search. The number of collaborations established, IP assets shared, and research progress made demonstrates the effect WIPO Re:Search is having on product development worldwide and the impact it will have on health.

BVGH is always looking for new opportunities to apply IP assets to neglected tropical diseases, malaria, and tuberculosis product development. If you plan to be in Seattle, please schedule a time to drop by our offices to discuss your research interests and needs.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
Special Announcement

Will you be attending the 2016 BIO International Convention? If so, stop by the BVGH Africa pavilion (booth #7409) to say hello to our exhibitors representing several African countries. WIPO Re:Search Members will be exhibiting at the pavilion. For more information, please email Katy Graef.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

Malaria Collaborations by Product

Drugs: 14
Diagnostics: 7
Basic Research: 11
**Cornerstones of Collaboration**

Dr. Manu Prakash, Assistant Professor of Bioengineering, Stanford University, will provide Dr. Ricardo Izurieta, Associate Professor, Department of Global Health, University of South Florida (USF), with paper microscopes (Foldscopes). Ricardo will use the Foldscopes to test soil samples for helminth eggs. Ricardo will also send helminth samples to Manu, which he will use during his refinement of the Foldscope.

**WIPO**, the Japan Patent Office (JPO), and the Intellectual Property Office of the Philippines (IPOPHL) held the “Regional Workshop on IP Management around WIPO Re:Search and WIPO GREEN” in the Philippines. Representatives from Novartis and Takeda described the application of IP to economic and social development during the event.

![Mr. Seiji Mori, Head of Operations (IP), IP Department, Takeda, presented WIPO Re:Search at the workshop.](image)

**Partnership Hub Central**

BVGH was invited to make recommendations to the United Nations Secretary General’s High-Level Panel on Access to Medicines. Jennifer Dent highlighted the success of WIPO Re:Search as an example of how the biopharmaceutical industry is sharing its IP to advance the development of products for diseases of poverty. Jennifer’s comments and recommendations shared during an open dialogue session can be viewed here: [1], [2], [3].

Jennifer visited Pfizer to update on the progress of WIPO Re:Search and to gain feedback on the Consortium from Pfizer’s team.
BVGH FundFinder Featured Funding Announcement

Endemic-Region Challenge Grants to Exploit the MMV Pathogen Box

MMV is issuing a call for proposals from endemic-country scientists to exploit the rich selection of active compounds within its Pathogen Box and boost neglected disease drug discovery. The goal is to kindle new research in disease-endemic countries, thus Principal Investigators must be based in endemic regions, where the majority of the work will be undertaken. Project proposals are expected to be at the concept stage (i.e. no prior experimental work is required) and work needs to be completed within one year.

Funding amount: $50,000 USD  
Funder: Medicines for Malaria Venture (MMV)  
Deadline: April 30, 2016 at 12 noon CET  
Eligibility: Scientists based in a neglected disease-endemic country

For more information about BVGH FundFinder, please email Roopa Sriram.

Highlighted Contributions

Featured this month is a contribution to be submitted by Janssen to the WIPO Re:Search Database.
Janssen, the Pharmaceutical Companies of Johnson & Johnson, is making available its Jump-stARter Library to the WIPO Re:Search database. The library represents 80,000 high quality compounds that have been carefully selected to represent chemical diversity. This library is available for WIPO Re:Search Members for use in screens to aid the small molecule drug discovery for NTDs, tuberculosis, and malaria.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.

---

**WIPO Re:Search In the News**

The Wellcome Trust described the WIPO Re:Search collaboration between Professor Fidelis Cho-Ngwa, Head, ANDI Centre of Excellence for Onchocerciasis Drug Research, University of Buea, and Merck KGaA, Darmstadt, Germany in a recent publication on its website. The collaborators were awarded a Pathfinder Award by the Wellcome Trust to support their onchocerciasis drug discovery efforts.

WIPO published the results of last year’s international patent and trademark filings. WIPO Re:Search Member, Novartis, topped the list of organizations filing the most Madrid System applications. WIPO Director General Francis Gurry noted that, “Global intellectual property applications […] provide a good indication of the incidence and location of innovation. We see through this indicator that, while the United States of America maintains its premier position, the geography of innovation continues to shift and to evolve, with Asia, and in particular Japan, China, and the Republic of Korea, forming the predominant geographical cluster.”

---

**Upcoming Global Health Events**

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>May</td>
<td>Keystone Symposium: New Approaches to Vaccines for Human and 22-26 Vet Tropical Diseases</td>
<td>Cape Town, South Africa</td>
<td>Website</td>
</tr>
<tr>
<td>June</td>
<td>2016 BIO International Convention</td>
<td>San Francisco, CA</td>
<td>Website</td>
</tr>
<tr>
<td></td>
<td>6-9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>June</td>
<td>Gordon Research Conference: Biology of Host-Parasite Interactions</td>
<td>Newport, RI</td>
<td>Website</td>
</tr>
<tr>
<td></td>
<td>12-17</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
May 2016

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

WIPO and BVGH will be featuring WIPO Re:Search at several key events over the coming weeks. A WIPO Re:Search symposium will be held at the World Health Assembly in Geneva on May 26th, featuring panelists from Sanofi, MSD, and the University of Buea, and the Minister of Health of Ethiopia. If you will be in Geneva for the World Health Assembly please plan to join us for this important program.

Several WIPO Re:Search Members from Africa, including the African Institute of Biomedical Science and Technology (AiBST), Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Noguchi Memorial Institute for Medical Research (NMIMR), and the University of Buea, will be representing their institutes and countries at the 2016 BIO International Convention and Africa pavilion.

I encourage all WIPO Re:Search Members attending the Convention to take advantage of this opportunity to learn about these Members’ research and partnering interests and discuss collaboration ideas.

I am pleased to welcome our newest Members, Case Western Reserve University and Armauer Hansen Research Institute (AHRI), to WIPO Re:Search.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
Special Announcements

With the sponsorship of the Permanent Mission of Ethiopia in Geneva, WIPO has organized a WIPO Re:Search event, which will be held concurrent to the World Health Assembly on May 26, 2016. BVGH and WIPO encourage all WIPO Re:Search Members participating in the World Health Assembly to attend this event. Click here for more information.

Will you be attending the 2016 BIO International Convention? If so, stop by the BVGH Africa pavilion (booth #7409) to say hello to our exhibitors representing several African countries. WIPO Re:Search Members will be exhibiting at the pavilion. For more information, please email Katy Graef.

The sub-Saharan Africa pavilion is made possible through the generous sponsorship of Celgene Corporation; Genentech, Inc.; Gilead Sciences; Global Good, Intellectual Ventures; Janssen, the Pharmaceutical Companies of Johnson & Johnson; Just Biotherapeutics, Inc; MSD*; Pfizer; Sanofi; SCYNEXIS, Inc.; Takeda; US Pharmacopeial Convention; and Viamet.

*Known as Merck & Co., Inc. in the US and Canada

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.
Cornerstones of Collaboration

Professor Alan Cowman of Walter and Eliza Hall Institute of Medical Research (WEHI) and Infection and Immunity Division Head, gave a seminar on the biology of malaria drug discovery targets at MSD’s West Point, Pennsylvania, site. During his visit, Alan and MSD* discussed recent collaboration results and next steps of their malaria drug discovery efforts.
New Members Announcement

We are pleased to announce that Case Western Reserve University and Armauer Hansen Research Institute (AHRI) have joined WIPO Re:Search.

Based in Cleveland, Ohio, Case Western Reserve University is home to researchers performing malaria and schistosomiasis vaccine development and malaria drug discovery. Case Western Reserve University researchers are also studying the epidemiology of lymphatic filariasis and schistosomiasis, immunology of malaria, and dengue virus pathogenesis.

The Armauer Hansen Research Institute (AHRI) was founded in 1970 by the Ministry of Health of Ethiopia and the Norwegian and Swedish Save the Children organizations. Activities at AHRI span basic, epidemiological, and translational research on tuberculosis, leprosy, malaria, and leishmaniasis.
Partnership Hub Central

Jennifer Dent presented WIPO Re:Search as an example of the biopharmaceutical industry's involvement in global health during her guest lecture for the Wharton Health Care Management Department’s "Private Sector Participation in Global Health Development" course.


BVGH FundFinder Featured Funding Announcement

CaringCrowd
Powered by Johnson & Johnson, CaringCrowd is a crowdfunding source dedicated to funding public health projects. Project owners can find donors, and donors who want to support global public health can find projects that need funding. Project owners set a fundraising goal and deadline, and donors interested in a project make a funding pledge. A project must reach its funding goal within its specified fundraising period – 15 to 90 days – in order to receive donations.

Funding amount: Open – project owner sets funding goal
Funder: Crowdfunding – open to all
Deadline: 15 – 90 days after posting project
Eligibility: Project owner must be affiliated or partnered with a U.S.-based 501(c)(3) organization.

For more information about BVGH FundFinder, please email Roopa Sriram.

Highlighted Contribution

Featured this month is a contribution submitted by Alnylam Pharmaceuticals to the WIPO Re:Search Database.

RNA interference platform technology IP and know-how (ID: 1362)
Alnylam is the world leader in the research and development of drugs designed to take advantage of the body's natural mechanism of RNA interference (RNAi). Provided here is a collection of granted patents and pending patent applications, which cover small interfering RNA compositions and methods of using such compositions in a variety of applications including as human therapeutics. In addition, pharmaceutical formulations, chemical modifications, and delivery modalities are covered.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.
WIPO Re:Search In the News

WIPO Re:Search was cited as a good example of tech transfer initiatives during a WIPO Committee on Development and Intellectual Property (CDIP) meeting. Click here to read about the CDIP meeting.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 15-18</td>
<td>LESI Annual Conference</td>
<td>Beijing, China</td>
<td>Website</td>
</tr>
<tr>
<td>May 23-28</td>
<td>69th World Health Assembly</td>
<td>Geneva, Switzerland</td>
<td>Website</td>
</tr>
<tr>
<td>June 6-9</td>
<td>2016 BIO International Convention</td>
<td>San Francisco, California</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada
In This Issue

- WHA WIPO Re:Search Event
- Special Announcement
- WIPO Re:Search Statistics
- Cornerstones of Collaboration
- Partnership Hub Central
- Funding Announcement
- Member Spotlight
- Highlighted Contributions
- WIPO Re:Search in the News
- Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

WIPO Re:Search and its Members were featured during two key events over the past month. WIPO Re:Search panel discussion concurrent to the World Health Assembly, which featured panelists from MSD, Sanofi, and the University of Buea.


Both events were highly successful in raising awareness of WIPO Re:Search, its activities and impact, and the interests and capabilities of its Members.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

World Health Assembly: WIPO Re:Search Side Event

With the sponsorship of the Permanent Mission of Ethiopia in Geneva, WIPO organized and hosted a WIPO Re:Search side event at the WHO World Health Assembly in Geneva. H.E. Dr. Kesetebirhan Admasu, Minister of Health, Ethiopia, opened the event by describing the value of WIPO Re:Search to developing countries. Minelik Alemu Getahun, Assistant Director General, Global Issues Sector, WIPO,
Participants in the well-attended event listened to a lively discussion about WIPO Re:Search and the impact the Consortium has had to date.

WIPO Re:Search Panel from left to right: Dr. Anatole Krattiger (WIPO), Martin Bernhardt (Sanofi), Jennifer Dent (BVGH), H.E. Dr. Kesetebirhan Admasu (Ministry of Health, Ethiopia), Minelik Alemu Getahun (WIPO), Dr. Fidelis Cho-Ngwa (University of Buea), Laurel Vogelsang (MSD*), and Tom Bombelles (WIPO).

*Known as Merck & Co., Inc. in the US and Canada

**Special Announcement**

The Eighth European & Developing Countries Clinical Trials Partnership (EDCTP) Forum will take place on November 6-9, 2016 in Lusaka, Zambia. The Forum theme is: defeating poverty-related and neglected diseases in Africa: harnessing research for evidence-informed policies. The deadline for oral or poster presentation abstracts is July 4, 2016. Scholarships for early career scientists are available. Click here to submit an abstract and apply for a scholarship.

**WIPO Re:Search Statistics**
To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

*Includes lymphatic filariasis, neurocysticercosis, onchocerciasis, schistosomiasis, and soil-transmitted helminthiases

---

**Cornerstones of Collaboration**

Michael Hsieh, Strewalt Endowed Director and Principal Investigator of the Schistosomiasis Resource Center at the Biomedical Research Institute (BRI) shared positive controls (genomic DNA) for *Schistosoma mansoni* and the intermediate host, the snail *Biomphalaria pfeifferi* with Olaoluwa (Pheabian) Akinwale, Director of Research (Neglected Tropical Diseases) and Principal Investigator of the Molecular Parasitology Research Laboratory at the Nigerian Institute of Medical Research (NIMR). Pheabian will be using these positive controls while characterizing the snails and looking for *S. mansoni* in a particular region of Nigeria and the prevalence could inform treatment policy.

Following BVGH’s recommendation, Dr. Fidelis Cho-Ngwa, Associate Professor, Biotechnology Unit, University of Buea, applied for the Medicines for Malaria Venture (MMV) Endemic-Region Challenge Grant for its new Pathogen Box. BVGH is pleased to announce that Fidelis was awarded the grant, which will support his examination of the Pathogen Box using his *in vitro* and *in vivo* onchocerciasis screens.
Dr. David Reddy, CEO, Medicines for Malaria Venture (left) and Dr. Fidelis Cho-Ngwa, Associate Professor, Biotechnology Unit, University of Buea (right) at the WHO World Health Assembly Novartis Access side event

**Partnership Hub Central**

BVGH hosted the 2nd Africa pavilion at the 2016 Biotechnology Innovation Organization (BIO) International Convention in San Francisco. Several WIPO Re:Search Members were represented at the pavilion including the University of Buea (Cameroon), the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) and the Noguchi Memorial Institute for Medical Research (NMIMR) (Ghana), the African Institute of Biomedical Science and Technology (AIBST) (Zimbabwe), University of Ibadan and Nigerian Institute of Medical Research (NIMR) (Nigeria), University of Bamako (Mali), and Cheikh Anta Diop University (Senegal). Additional WIPO Re:Search Members, including the University of California, San Francisco, Johnson & Johnson, and MSD*, visited the pavilion and met with the exhibitors.

Jennifer Dent, President, BVGH, also featured WIPO Re:Search during her presentation at the Convention’s 12th Annual Biotechnology Entrepreneurship Boot Camp.
Dr. Augustina Angelina Syverken, Postdoctoral Fellow, Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) (left) and James Greenwood, President & CEO, BIO (right)

The Africa pavilion was made possible through the generous sponsorship of Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Global Good, Intellectual Ventures; Just Biotherapeutics; Janssen, the Pharmaceutical companies of Johnson & Johnson; MSD*; Pharmaceutical Research and Manufacturers of America (PhRMA); Pfizer, Inc.; Sanofi; SCYNEXIS, Inc.; Takeda Pharmaceutical Company; the US Pharmacopeial Convention; and Viamet Pharmaceuticals.

*Known as Merck & Co., Inc. in the US and Canada

---

**BVGH FundFinder Featured Funding Announcement**

**BD Biosciences Research Grants: Infectious Diseases**

BD Biosciences Research Grants aim to reward and enable important research by providing vital funding to scientists pursuing innovative experiments that advance the scientific understanding of disease. A total of $140,000 worth of BD Biosciences research reagents are awarded annually to 14 scientists. Through the grant program, BD Biosciences works to support innovation in research and development, helping to define the next generation of scientific breakthroughs.

**Funding amount:** $10,000 worth of BD Biosciences research reagents
Member Request

The Council on Health Research for Development (COHRED) Research Fairness Initiative (RFI) aims to create a reporting system that encourages governments, business, organizations, and funders to share their efforts to develop fair partnerships and, in the process, develop better guidelines and benchmarks that will increase global capacity to deal with the challenges of global health, equity, and development. Through its Global Consultation 3, COHRED is soliciting comments, examples, ideas, and suggestions for implementation of the RFI. Click here to learn more and share your input and ideas. Please submit feedback by June 30, 2016.

Highlighted Contributions

Featured this month are two contributions submitted by GlaxoSmithKline (GSK) to the WIPO Re:Search Database.

Method for inhibiting MetAP2 and inhibitor identification methods (ID: 2064)
Methods are disclosed for identifying inhibitors of methionine aminopeptidase type 2 (hMetAP2) and for inhibiting hMetAP2 using inhibitors with certain structural, physical, and spatial characteristics. Preparation of triazole derivative inhibitors is also described.

GSK know-how from abandoned patents available for NTD research and development (ID: 1408)
GSK will consider requests for help in pursuing projects aimed at developing medicines to treat one of the 21 NTDs in least developed countries where the company may have relevant expertise. The subject matter in some of GSK’s abandoned patent applications may provide an important know-how entry point for third party programs. GSK is willing to share any further know-how that it may have in relation to these areas.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.

WIPO Re:Search In the News

The WIPO Re:Search agreement between GlaxoSmithKline (GSK) and the Center for World Health & Medicine (CWHM) was described in an article on open-source research in Nature.
<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept. 18-22</td>
<td><strong>International Congress for Tropical Medicine and Malaria (ICTMM)</strong></td>
<td>Brisbane, Australia</td>
<td>Website</td>
</tr>
<tr>
<td>Nov. 4-7</td>
<td><strong>International Meeting on Emerging Diseases and Surveillance (IMED)</strong></td>
<td>Vienna, Austria</td>
<td>Website</td>
</tr>
<tr>
<td>Nov. 13-17</td>
<td><strong>American Society of Tropical Medicine &amp; Hygiene (ASTMH) Annual Meeting</strong></td>
<td>Atlanta, Georgia</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada*
July 2016

In This Issue
- WIPO Re:Search Statistics
- Cornerstones of Collaboration
- New Member Announcement
- Partnership Hub Central
- Funding Announcement
- Member Spotlight
- Highlighted Contributions
- WIPO Re:Search In the News
- Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

It’s hard to believe we are already halfway through 2016. I am pleased to share the 2016 BVGH Partnership Hub Mid-Year Report with you. This report presents BVGH’s accomplishments towards our 2016 WIPO Re:Search goals and deliverables. In the first half of 2016, BVGH established six new agreements, recruited four new Members, and publicized WIPO Re:Search and its achievements through various conferences and media.

During the second half of 2016, BVGH will continue to establish new agreements and support the other ongoing and advancing collaborations. Currently, there are five collaborations in advanced stages of negotiations. Many more are in early negotiations between Members. We look forward to another productive and fruitful half-year ahead.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

Special Announcement
The 2016 BVGH Partnership Hub Mid-Year Report is now available. This report presents BVGH’s WIPO Re:Search accomplishments during the first half of 2016. Click here to download the report.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

**Cornerstones of Collaboration**

Janssen Research & Development will provide Dr. Jennifer Keiser, Head, Helminth Drug Development Unit, Swiss Tropical and Public Health Institute (Swiss TPH) with a targeted set of small molecule receptor agonists to screen against hookworms in vitro.
Alnylam Pharmaceuticals will provide Prof. Stefan Kappe, Director for Translational Science, and Dr. Ryan Steel, Postdoctoral Scientist, Center for Infectious Disease Research (CID Research), with a set of siRNAs targeting a hepatocyte receptor. The siRNAs will be used to assess the result of knocking down the receptor on *P. falciparum* invasion of hepatocytes in vivo.

Dr. Ravi Selvaganapathy, Professor, Department of Mechanical Engineering, McMaster University, met with collaborators at PATH last month. During his visit to Seattle, Ravi met with BVGH and described his current research projects and innovations. Check out this Snapshot’s “Member Highlight” section to learn about one of Ravi’s innovative microdevices.

**New Member Announcement**

We are pleased to announce that the Fondation Congolaise pour la Recherche Medicale (FCRM) has joined WIPO Re:Search.

The Fondation Congolaise pour la Recherche Medicale (FCRM) was established in 2008 to support research, public health, and higher education in Brazzaville, the Republic of the Congo. Researchers at FCRM focus on *Plasmodium* genetic diversity, epidemiology, and drug resistance; natural products discovery; molecular mechanisms of host immune response to *P. falciparum*; tuberculosis; HIV/AIDS; and bacterial, viral, and parasitic diarrhea.

**Partnership Hub Central**

Dr. Ujwal Sheth, Associate Director, BVGH, gave a global health seminar on WIPO Re:Search at the Center for Infectious Disease Research (CIDR) in Seattle. Following the event she met with several group leaders to learn more about their NTD research and partnering interests.

**BVGH FundFinder Featured Funding Announcement**

**Career Development Fellowships**

This call for proposals will provide funding to initiatives that aim to support junior to mid-career researchers to train and develop their clinical research skills. The objectives are:
1. To promote career development and retention of postdoctoral researchers and postgraduate medical researchers in the research field and in sub-Saharan Africa
2. To equip the fellows with the ability to establish themselves as independent researchers and with the skills to initiate and manage their own research and team at host organizations in sub-Saharan Africa.

**Funding amount:** €150,000 over a maximum of three years  
**Funder:** European & Developing Countries Clinical Trials Partnership (EDCTP)  
**Deadline:** Opens October 3, 2016, closes February 28, 2017  
**Eligibility:** Applicant must be employed at an established entity in sub-Saharan Africa and intend to remain at this organization for two years after expiration of the grant. Applicant must have a PhD and up to five years’ relevant postdoctoral experience or a medical doctor with up to five years’ research experience.

For more information about BVGH FundFinder, please email Roopa Sriram.

---

**Member Spotlight**

Dr. Ravi Selvaganapathy, Professor, Department of Mechanical Engineering, **McMaster University**, has developed an inexpensive nanoliter well assay that increases the speed of detection of bacteria within a sample. A sample is spread on the device, which has thousands of individual nanoliter wells. By partitioning a sample into small wells, the device effectively creates a concentration of bacteria that is several fold higher than that of the original sample. Ravi’s group has demonstrated that the device can detect bacterial growth from a $10^4$ cfu/ml sample in ~1 hour. Click [here](#) to learn more.

---

**Highlighted Contributions**

Featured this month are two contributions submitted by **Eskitis Institute** to the **WIPO Re:Search Database**.

**Natural Products and Bioaffinity Screening (ID: 2581)**  
The **Nature Bank** is an integrated drug discovery platform based on natural products from Australia, China, and Papua New Guinea. It comprises over 45,000 samples of plants and marine invertebrates, over 200,000 semi-purified fractions, over 3,250 pure compounds, and over 400 naturally-occurring fragments. The Nature Bank is enhanced for drug-like characteristics in accordance with Lipinski’s rules and can be screened against a variety of drug target proteins including those from parasite proteomes.

**Bioaffinity Mass Spectrometry (ID: 2601)**  
The Eskitis Institute has established a mass spectrometry-based medium-throughput screening platform capable of identifying compounds binding to proteins, delivering drug leads and potential pathways to crystallization and structure-based design. Proteins can be analyzed in their folded, native state without labelling.

For more information or to discuss potential collaborations regarding this technology, please...
**WIPO Re:Search In the News**

The Office of the United States Trade Representative's [2016 Special 301 Report](#) highlighted WIPO Re:Search as a best practice in the area of intellectual property rights protection and enforcement.

---

**Upcoming Global Health Events**

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept.</td>
<td>2016 International Congress for Tropical Medicine and Malaria 18-22 (ICTMM)</td>
<td>Brisbane, Australia</td>
<td>Website</td>
</tr>
<tr>
<td>Nov.</td>
<td>International Meeting on Emerging Diseases and Surveillance (IMED) 4-7 2016</td>
<td>Vienna, Austria</td>
<td>Website</td>
</tr>
<tr>
<td>Nov.</td>
<td>American Society of Tropical Medicine &amp; Hygiene (ASTMH) 65th 13-17 Annual Meeting</td>
<td>Atlanta, Georgia</td>
<td>Website</td>
</tr>
</tbody>
</table>

---

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada*
August 2016

In This Issue

WIPO Re:Search Statistics
Cornerstones of Collaboration
Partnership Hub Central
Funding Announcement
Highlighted Contributions
Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

BVGH and WIPO are busy planning for the next five years of WIPO Re:Search! We look forward to your input and feedback on our strategic plan and vision of the direction of WIPO Re:Search.

I am pleased to report that we have selected dates and locations for upcoming WIPO Re:Search Member meetings. Mark your calendar for a WIPO Re:Search meeting at the World Health Assembly, May 22 -26th in Geneva next year. If you are planning to attend the 2016 WHO-WIPO-WTO Trilateral Symposium, the American Society of Tropical Medicine and Hygiene (ASTMH) 65th Annual Meeting, or the 2016 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) General Assembly, please join WIPO and colleagues to learn about WIPO Re:Search’s plans over the next five years. Dates and locations are captured below.

In 2013, the Government of Australia provided WIPO Re:Search with funds in trust (FIT) to support sabbaticals for African WIPO Re:Search Member scientists. Australia has committed additional funds (FIT2), which will be used to support additional hosting arrangements for scientists from East Africa and the Asia Pacific. Tom Bombelles and I are in Australia this week to meet with the Government of Australia and begin preparations for FIT2. If you would like to learn more about FIT2, please email Katy Graef.

Ujwal Sheth will be presenting WIPO Re:Search at the 2016 International Congress for Tropical Medicine and Malaria (ICTMM) in Brisbane, Australia next month. Contact Ujwal if you are attending and would like to meet.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
**Special Announcement**

BVGH and WIPO are currently preparing a WIPO Re:Search medium-term five-year strategic plan (MTSP). We will share a draft of this plan before the end of the year for Member feedback.

Instead of a single WIPO Re:Search Annual meeting in 2016, WIPO is planning Member meetings concurrent to the following events. If you would like to attend one of these satellite WIPO Re:Search meetings, please email Meg Shafrudeen at WIPO and specify which meetings you would like to attend.


2. **Week of November 13th-18th, 2016, Atlanta** – American Society of Tropical Medicine and Hygiene (ASTMH) 65th Annual Meeting


The WIPO Re:Search Member Meeting will be held alongside the World Health Assembly in Geneva, during the week of May 22nd-26th, 2017. For more information about the meeting, contact Tom Bombelles.

---

**WIPO Re:Search Statistics**

![Agreements: 104, Members: 106](image)

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.
Cornerstones of Collaboration

Pfizer will provide Dr. Jennifer Keiser, Head, Helminth Drug Development Unit, Swiss Tropical and Public Health Institute (Swiss TPH) with a set of small molecule receptor agonists to screen against hookworms in vitro.

Partnership Hub Central

In 2013, the Government of Australia provided funds in trust (FIT) to WIPO, which were used to support sabbaticals for African researchers. Six researchers from Cameroon, Egypt, Ghana, Nigeria, and South Africa were placed at biopharmaceutical companies and leading universities for periods of three months to one year. WIPO’s recent Global Challenges Report, “Sharing Innovation and Building Capacity to Fight Neglected Tropical Diseases: A Selection of WIPO Re:Search Fellowship Stories,” describes the experiences of these six researchers and their hosts. Click here to download the report.

WIPO convened the first meeting of the WIPO Re:Search Advisory Committee. The Committee, which is chaired by Dr. Peter Hotez, President and Director, Sabin Vaccine Institute, is responsible for providing strategic advice relevant to the activities and long-term development of WIPO Re:Search.

BVGH FundFinder Featured Funding Announcement

Going Global Innovation
Going Global Innovation (GGI) is specifically designed to promote and enhance Canada’s international innovation efforts. The program supports Canadian researchers who aim to commercialize technologies by pursuing collaborative international research and development (R&D) opportunities through partnerships with key players in foreign markets.

Funding amount: $58,000 USD
Funder: Canadian International Development Agency
Deadline: Applications are accepted on an on-going basis
Eligibility: Eligible beneficiaries are Canadian researchers from small or medium size enterprises, universities, and non-government research centers.
Highlighted Contributions

Do you have an asset that you are willing to contribute to another WIPO Re:Search Member to further neglected tropical disease, malaria, or tuberculosis research and development? Email Ujwal Sheth to learn how you can have your asset summarized in the WIPO Re:Search Database and featured in this section of an upcoming Snapshot newsletter.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept</td>
<td>2016 International Congress for Tropical Medicine and Malaria 18-22 (ICTMM)</td>
<td>Brisbane, Australia</td>
<td>Website</td>
</tr>
<tr>
<td>Nov</td>
<td>International Meeting on Emerging Diseases and Surveillance (IMED) 4-7 2016</td>
<td>Vienna, Austria</td>
<td>Website</td>
</tr>
<tr>
<td>Nov</td>
<td>American Society of Tropical Medicine &amp; Hygiene (ASTMH) 65th 13-17 Annual Meeting</td>
<td>Atlanta, Georgia</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada
Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

BVGH is excited about the very busy season ahead! The BVGH team is planning on attending and representing WIPO Re:Search at several upcoming key meetings including the 2016 International Congress for Tropical Medicine and Malaria (ICTMM) in Brisbane, Australia; the Eighth European & Developing Countries Clinical Trials Partnership (EDCTP) Forum in Lusaka, Zambia; the 65th Annual ASTMH Meeting in Atlanta, Georgia; and the TTS Latin America Meeting in Medellin, Colombia. We look forward to communicating the Consortium’s achievements, discussing collaboration ideas with current Member scientists, and engaging potential new Member organizations during these events.

BVGH will also be working with WIPO to launch the second WIPO Re:Search developing country scientist sabbatical program, which is supported by Funds in Trust (FIT) from IP Australia. This program (FIT2) will focus on the placement of scientists from East Africa and the Asia Pacific Region at Australian research institutes for research training. To read about the first WIPO Re:Search developing country scientist sabbatical program, click here. If you would like to learn more about FIT2, please email Katy Graef.

I am pleased to welcome our newest Member, the University of Georgia (UGA).

Ujwal Sheth will be presenting WIPO Re:Search at the 2016 International Congress for Tropical Medicine and Malaria (ICTMM) in Brisbane, Australia this month. Contact Ujwal if you are attending and would like to meet.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.
Special Announcement

BVGH and WIPO are currently preparing a WIPO Re:Search medium-term five-year strategic plan (MTSP). WIPO will host two meetings to obtain Members’ input on the plan:

**Geneva, Switzerland:** Wednesday, October 26th, 9am – 1pm CEST
**Washington, DC, USA:** Wednesday, November 30th, 8am – 12pm EST (date and time subject to change)

If you would like to attend one of these meetings, please email Meg Sharaabudeen at WIPO and specify which meeting you are planning to attend.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.
**Cornerstones of Collaboration**

**Takeda** will provide Prof. Conor Caffrey, Nematode and Trematode Core Director, Center for Discovery and Innovation in Parasitic Diseases (CDIPD), University of California, San Diego (UCSD) with a targeted set of compounds to screen against *Schistosoma mansoni* in *vitro*. These screens will extend Conor’s earlier screening data to include a new chemical series targeting the same *S. mansoni* protein.

Dr. Oluwagbemiga Aina, Senior Research Fellow, *Nigerian Institute of Medical Research* (NIMR), will provide Dr. Lawrence Ayong, Head, Malaria Research Group, Centre Pasteur du Cameroun (CPC), with a set of natural product extracts believed to have antimalarial activities. Lawrence will screen the extracts against *P. falciparum* using his *in vitro* assay.

**New Member Announcement**

We are pleased to announce that the *University of Georgia* (UGA) has joined WIPO Re:Search.

Located in Athens, Georgia, the University of Georgia (UGA) is the state’s oldest, most comprehensive, and most diversified institution of higher education. Its Center for Tropical & Emerging Global Diseases (CTEGD) is built on a strong foundation in parasitology, immunology, cellular and molecular biology, biochemistry, and genetics. CTEGD maintains close connection with the Division of Parasitic Diseases at the US Centers for Disease Control and Prevention (CDC) and the Emory Vaccine Center.
Researchers at CTEGD study the immunology of schistosomiasis and lymphatic filariasis, metabolic pathways of trypanosomatids and malaria parasites, and mechanisms of action of and modes of resistance to anthelmintics, among many other topics.

---

**BVGH FundFinder Featured Funding Announcement**

**Africa London Nagasaki Scholarship Fund**
The Africa London Nagasaki Scholarship Fund has been set up to support African scientists building a career in infectious disease research. The scholarship will allow African researchers to undertake an MSc in a subject relevant to the control of infectious disease in the developing world at either the Institute of Tropical Medicine, Nagasaki University (NEKKEN), Japan, or at the London School of Hygiene & Tropical Medicine (LSHTM), UK. The fund will support up to four scholarships per year.

**Funding amount:** Maximum of $50,000 USD to cover tuition fees, travel, and living expenses.
**Funder:** Africa London Nagasaki Scholarship Fund
**Deadline:** September 30, 2016
**Eligibility:** Applicants must be of African nationality and normally be resident in sub-Saharan Africa. They must have a first or upper second class BSc degree (or equivalent) in a relevant area and will usually have at least two years prior research experience. Candidates who apply to study in Japan must have a medical qualification and at least two years of clinical experience.

To learn more about BVGH FundFinder and to subscribe, click [here](#) or contact Lisel Koepfl.

---

**Highlighted Contributions**

Featured this month are two contributions submitted by the Center for World Health & Medicine (CWHM) to the [WIPO Re:Search Database](#).

**Structure Based Drug Design and Medicinal Chemistry (ID: 1881)**
The CWHM has an accomplished medicinal chemistry group with significant expertise in the design of compounds with the appropriate safety, pharmacokinetic, and pharmaceutical properties required for human development. The CWHM, in partnership with the University of Missouri, has state of the art chemistry facilities. The CWHM and University of Missouri chemists also have considerable expertise in structure-based drug design (SBDD) and have collaborations in place with molecular modelers to further enhance their capabilities. The CWHM will consider collaborative proposals to consult or collaborate on neglected disease targets using its medicinal chemistry design and synthetic skill sets.

**Pharmacokinetic/ADME evaluation of small molecule compounds (ID: 1902)**
The CWHM will consider collaborative proposals to evaluate the pharmacokinetic properties of tool or candidate compounds. The CWHM possesses the necessary equipment and expertise to conduct *in vivo* studies in rodents and complete bioanalytical analyses of samples using LC/MS/MS. *In vitro* metabolism and protein binding and stability studies can also be performed.

For more information or to discuss potential collaborations regarding this technology, please contact [Ujwal Sheth](#).
Intellectual Property Watch featured an International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) sponsored interview with Jennifer Dent about WIPO Re:Search and its relevance to the recent UN High Level Panel on Access to Medicines discussions.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov.</td>
<td>Eighth European &amp; Developing Countries Clinical Trials Partnership</td>
<td>Lusaka, Zambia</td>
<td>Website</td>
</tr>
<tr>
<td>6-9</td>
<td>(EDCTP) Forum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nov.</td>
<td>American Society of Tropical Medicine &amp; Hygiene (ASTMH) 65th Annual Meeting</td>
<td>Atlanta, Georgia</td>
<td>Website</td>
</tr>
<tr>
<td>13-17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>March</td>
<td>Gordon Research Conference: Tropical Infectious Diseases</td>
<td>Galveston, Texas</td>
<td>Website</td>
</tr>
<tr>
<td>12-17</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada
October 2016

In This Issue

WIPO Re:Search Statistics
Cornerstones of Collaboration
Partnership Hub Central
Funding Announcement
Member Spotlight
Highlighted Contributions
WIPO Re:Search In the News
Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

As we move into the final quarter of the year, BVGH is looking forward to featuring WIPO Re:Search at several upcoming events. Please let us know if you will be attending any of these meetings so we can connect and update on your research and partnering priorities.

Katy Graef will present WIPO Re:Search at the 2016 Global Humanitarian Technology Conference in Seattle. In November I will be presenting at the Eighth European & Developing Countries Clinical Trials Partnership (EDCTP) Forum in Lusaka, Zambia and the TTS Latin America Meeting in Medellin, Colombia. The BVGH team will be attending the 65th Annual ASTMH Meeting in Atlanta where they will manage a workshop, “Strategies to Combat Drug Resistance in STH”, and H3D: Malaria, Tuberculosis and Neglected Tropical Diseases: Progress in Drug Discovery and Development in Cape Town, South Africa. If you will be attending any of these meetings and would like to meet, please reach out to Cathy, Katy, or Ujwal.

All of us at BVGH wish to extend our congratulations to Professor Manu Prakash, Stanford University, for winning one of this year’s MacArthur Foundation “genius grants”. Manu – the creator of the Foldscope, a microscope made of paper – participated in a WIPO Re:Search collaboration with Dr. Wellington Oyibo, University of Lagos. Click here to learn more about Manu’s collaboration with Wellington.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
**Special Announcement**

BVGH and WIPO are currently preparing a WIPO Re:Search medium-term five-year strategic plan (MTSP). WIPO will host two meetings to obtain Members’ input on the plan:

**Geneva, Switzerland:** Wednesday, October 26th, 9am – 1pm CEST  
**Washington, DC, USA:** Wednesday, November 30th, 8am – 12pm EST (date and time subject to change)

If you would like to attend one of these meetings, please email Meg Sharafudeen at WIPO and specify which meeting you are planning to attend.

**WIPO Re:Search Statistics**

![Agreements 107 Members 107]

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.
Cornerstones of Collaboration

Janssen Research & Development will provide Professor Alan Cowman, Deputy Director and Joint Division Head, Division of Infection and Immunity, and Dr. Brad Sleebs, Senior Postdoctoral Fellow, Walter and Eliza Hall Institute of Medical Research (WEHI), with its Jump-stARter library (in accordance with certain agreed upon terms), a set of 80,000 chemically diverse, high-quality compounds that have been carefully selected to represent chemical diversity. Prof. Cowman and Dr. Sleebs will screen the Jump-stARter library against *P. falciparum in vitro*.

**Partnership Hub Central**

Dr. Ujwal Sheth, Associate Director, BVGH, presented WIPO Re:Search at the 2016 International Congress for Tropical Medicine and Malaria (ICTMM) in Brisbane, Australia. While at the meeting, Ujwal met with researchers from the Walter and Eliza Hall Institute of Medical Research (WEHI), Sabin Vaccine Institute, Eskitis Institute at Griffith University, Swiss Tropical and Public Health Institute (Swiss TPH), James Cook University, and the Australian National University (ANU). While in Australia, Ujwal visited WEHI and Monash University to discuss their partnering interests and to present the second WIPO Re:Search developing country scientist sabbatical program, which is supported by Funds in Trust (FIT) from IP Australia.
BVGH FundFinder Featured Funding Announcement

Next-Gen Supply Chain QuickFire Challenge
Johnson & Johnson Innovation and Janssen Supply Chain are looking to award a prize or a series of prizes to the person or team(s) who submits the best solution to key manufacturing and supply chain challenges that address the issues of higher costs and reliability in supply chains. Johnson & Johnson is looking for innovative methods to:

- Stabilize protein formulations in liquid stage without refrigeration
- Optimize process environment methodologies to significantly increase cell production titer (g/L) in the range of 50 to 100% improvement from common mAbs baseline
- Protect proteins from gastric digestion so as to enable oral absorption

Funding amount: Up to $75,000
Funder: Johnson & Johnson Innovation Labs
Deadline: November 2, 2016
Eligibility: An applicant must be a researcher in one of the following sectors: therapeutics, medical devices and diagnostics, health technologies, or consumer healthcare. Healthcare providers and government officials are not eligible to participate.

For more information about BVGH FundFinder, please email Lisel Koepl.

Member Spotlight

Professor Karl Hoffmann from Aberystwyth University is looking for stakeholders to comment on his concept note and take part in his proposal to establish a network of investigators exploring broad approaches to controlling the snail intermediate host of Schistosoma helminths. Karl is developing this proposal in response to the UK Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council’s (BBSRC) funding call for the establishment of networks for vector-borne disease research. Selected networks will be provided funding to coordinate events and support pump-priming projects, among other activities.

If you are interested in getting involved, please sign up to the BBSRC’s extranet to view Karl’s concept note and provide your comments. Your comments will be critical to demonstrating to the UK MRC and
Highlighted Contributions

Featured this month is a contribution submitted by the National Institutes of Health (NIH) to the WIPO Re:Search Database.

Monoclonal antibodies that bind or neutralize dengue virus (ID: 701)

The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheeth.

WIPO Re:Search In the News

In the lead-up to the World Intellectual Property Organization’s (WIPO) annual meeting of the Assemblies, WIPO Director General, Dr. Francis Gurry, cited WIPO Re:Search as an example of practical international cooperation at WIPO. Click here to read more.

WIPO Magazine featured Medicines for Malaria Venture (MMV) and described its strategy to build strong alliances to discover and develop new drugs to treat malaria.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name ..................................................................................</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov. 6-9</td>
<td>Eighth European &amp; Developing Countries Clinical Trials Partnership (EDCTP) Forum</td>
<td>Lusaka, Zambia</td>
<td>Website</td>
</tr>
<tr>
<td>Nov. 13-17</td>
<td>American Society of Tropical Medicine &amp; Hygiene (ASTMH) 65th Annual Meeting</td>
<td>Atlanta, Georgia</td>
<td>Website</td>
</tr>
<tr>
<td>March 12-17</td>
<td>Gordon Research Conference: Tropical Infectious Diseases</td>
<td>Galveston, Texas</td>
<td>Website</td>
</tr>
</tbody>
</table>
Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

The BVGH team will be presenting and representing WIPO Re:Search at several upcoming conferences.

Ujwal and Cathy will be attending the 65th Annual ASTMH Meeting in Atlanta. ASTMH presents an opportunity for our team to connect with Members from across the globe. If you or colleagues are heading to Atlanta, please reach out to Ujwal or Cathy to schedule a meeting.

Katy and I will both be presenting at the Eighth European & Developing Countries Clinical Trials Partnership (EDCTP) Forum in Lusaka, Zambia. We look forward to connecting with many of our African Members during the EDCTP Forum. Following EDCTP, Katy will be heading to South Africa to attend H3D: Malaria, Tuberculosis, and Neglected Tropical Diseases: Progress in Drug Discovery and Development in Cape Town. I will be giving a keynote address during the 1st Annual Tech Transfer Summit (TTS) Latin America Meeting in Medellin, Colombia.

WIPO will be hosting a WIPO Re:Search information session following the 28th IFPMA Assembly on November 30th. If you will be attending the Assembly or in Washington DC on the 30th, please join us to learn about the first five years of WIPO Re:Search and meet the WIPO Re:Search Advisory Committee members.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Special Announcement

WIPO invites all interested parties to attend an information session on WIPO Re:Search and meet the WIPO Re:Search Advisory Committee members. The meeting will be held on **Wednesday, November 30th, 2pm – 3pm** at the Ritz-Carlton Pentagon City. Click [here](#) to learn more.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

**WIPO Re:Search Kinetoplastid Collaborations**

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Diagnostics</th>
<th>Vaccines</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>2</td>
<td>1</td>
<td>17</td>
</tr>
</tbody>
</table>

**Participating WIPO Re:Search Members:**

- Center for Infectious Disease Research
- Drugs for Neglected Diseases Initiative
- Eisai
- Fundacao Oswaldo Cruz
- GlaxoSmithKline
- Institut Pasteur Korea
- McGill University
- National Institutes of Health
- Northeastern University
- Stanford University
- Swiss Tropical and Public Health Institute
- University of British Columbia
- University of California, San Diego
- University of California, San Francisco
- University of Dundee
- University of Washington
Cornerstones of Collaboration

Dr. Dylan Pillai, Associate Professor, University of Calgary, and colleagues at PATH recently published the results of their WIPO Re:Search collaboration. Through this collaboration, Dylan’s lab evaluated the efficacy of PATH’s non-instrumented nucleic acid amplification (NINA) heater coupled with a loop-mediated isothermal amplification (LAMP) assay to detect traveler’s malaria. Click here to read the paper. This is the second publication to result from Dylan and PATH’s collaboration. Click here to read their other paper.

Partnership Hub Central

WIPO hosted a Member meeting to obtain feedback and input on the WIPO Re:Search medium-term five-year strategic plan (MTSP). Click here to download the summary of the Member meeting.

Dr. Katy Graef presented WIPO Re:Search during a panel session at the 2016 Global Humanitarian Technology Conference in Seattle.

BVGH FundFinder Featured Funding Announcement

Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis Disease (RFA-AI-16-079)

The purpose of this award is to solicit research applications for milestone-driven projects focused on establishing proof-of-concept for and/or preclinical development of lead candidate vaccines targeting infection with *Mycobacterium tuberculosis* (Mtbc) and/or tuberculosis disease (TB).

**Proof-of-concept:** Projects must initiate with favorable candidates with demonstrated capacity to elicit an immune response in a relevant animal model for Mtbc infection and/or TB. Approaches to demonstrate proof-of-concept and evaluate candidate vaccines under a variety of informative experimental conditions are encouraged. Relevant aspects of the immune response should be investigated in the most appropriate models to gain further insight into the biological complexity underlying vaccine-induced immunity. The completion of proof-of-concept activities is expected to result in the selection of a lead candidate vaccine or related product deemed appropriate for subsequent preclinical product development.

**Preclinical development:** Proposed activities should focus on advancement of the lead candidate vaccine toward licensure. Applications that would significantly advance a candidate vaccine toward clinical usefulness are responsive and highly encouraged; however, projects are not required to result in a “final” product, nor is it necessary to propose completion of the product development process up to the point of readiness for clinical trials or validation within the
Highlighted Contributions

Featured this month a contribution submitted by Drugs for Neglected Diseases initiative (DNDi) to the WIPO Re:Search Database.

**Novel Leishmania donovani screening cascade (ID: 3101)**

A novel axenic amastigote *Leishmania* assay was developed and validated that reports only cytocidal molecules. It was used to screen a diversity-oriented synthesis library. The library is a set of structurally diverse small molecules that combine the complexity of natural products and the efficiency of high-throughput synthesis, with a higher ratio of sp3-hybridized atoms and stereocenters relative to compounds found in conventional screens. Two new chemical series with antileishmanial activity were identified via this novel screening assay. The new axenic assay has a significantly improved translation to an intracellular assay. Click [here](#) to learn more about this new assay.

For more information or to discuss potential collaborations regarding this technology, please contact [Ujwal Sheth](mailto:).
December 2016

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

With 2016 coming to a close, our team at BVGH is proud of what we have been able to accomplish over the first five years of WIPO Re:Search. Our membership has expanded to include more than 100 organizations representing 31 countries. More than 100 partnerships have been established and are advancing R&D and knowledge sharing across NTDs, malaria, and tuberculosis.

As we enter the Consortium’s next five years, BVGH and WIPO, with the guidance of our WIPO Re:Search Advisory Committee, are constructing a five-year strategic plan that will set goals and priorities, and describe our strategies to reach those goals. The plan will be presented during the 2017 World Health Assembly next May in Geneva.

I am pleased to welcome our two newest Members, Addis Ababa University (AAU) and the Center for Molecular Dynamics Nepal (CMDN).

As 2016 comes to a close, all of us at BVGH thank you for your support and participation in WIPO Re:Search. We wish you the very best over the holiday season and in the new year.

Sincerely,
Jennifer Dent
President, BVGH

Special Announcement

Have you presented or published the results of your WIPO Re:Search collaboration? If so, please let Katy Graef know so that we can feature your work in the 2016 WIPO Re:Search Annual Report as well as in an upcoming issue of the Snapshot newsletter.
To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.
Cornerstones of Collaboration

Takeda Pharmaceutical Company Limited will provide Professor Yossef Av-Gay, Division of Infectious Diseases, University of British Columbia (UBC), with a targeted set of compounds to screen against *M. tuberculosis* residing within macrophages.

Dr. Lawrence Ayong, Centre Pasteur du Cameroun (CPC), and colleagues at PATH recently published the results of their WIPO Re:Search collaboration. Through this collaboration, Lawrence evaluated the efficacy of PATH’s non-instrumented nucleic acid amplification (NINA) heater coupled with his reverse-transcription-loop-mediated isothermal amplification (RT-LAMP) assay to detect low-level parasitemia in malaria patients. Click here to read the paper.

New Member Announcement

We are pleased to announce that Addis Ababa University and the Center for Molecular Dynamics Nepal have joined WIPO Re:Search.

Addis Ababa University (AAU) is the oldest and largest higher learning and research institution in Ethiopia. Since its inception, the University has been Ethiopia's leading center for teaching, research, and community services. Researchers at the Aklilu Lemma Institute of Pathobiology at AAU perform a variety of research relevant to WIPO Re:Search including malaria control and prevention methods, schistosomiasis epidemiology, tuberculosis vaccine discovery and drug resistance profiles, and medicinal plants.

The Center for Molecular Dynamics Nepal (CMDN) is a service-oriented organization established and run by dedicated Nepali basic and applied scientists, social and public health experts, and a wide array of experts engaged in operations, management, and policy planning activities in Nepal. Biomedical research conducted at CMDN focuses on diseases prevalent in Nepal including tuberculosis, leprosy, malaria, and other infectious diseases.
Partnership Hub Central

The BVGH team engaged numerous researchers from current and potential new WIPO Re:Search Member organizations in partnership discussions while attending several recent conferences and events. As a keynote speaker at the 1st **Tech Transfer Summit** (TTS), Latin America conference, Jennifer Dent presented WIPO Re:Search as an example of how pharmaceutical companies are contributing their IP and resources to impact global health.

Jennifer and Ujwal met with representatives from WIPO Re:Search Company Members at the 28th **International Federation of Pharmaceutical Manufacturers & Associations** (IFPMA) Assembly. After the Assembly, Jennifer presented WIPO Re:Search’s first five years of activities and achievements at a WIPO Re:Search informational meeting organized by WIPO.

---

**BVGH FundFinder Featured Funding Announcement**

**African Researchers’ Small Grants Program**
The African Researchers’ Small Grants Program is comprised of two small grant funding tracks: 1) small grants for junior researchers and 2) small grants for mid-career and/or senior researchers. The small grants for junior researchers are tailored to African researchers at the Masters or PhD level (including students). The aim is for young upcoming researchers not only to gain experience in research but also in the grant application and management system.

Applicants for the mid-career and/or senior researchers’ small grants scheme will have to demonstrate that the proposed research or activity is aligned with their country/program interests and has potential institutional/individual capacity-building impact.

**Funding amount:** $25,000 USD  
**Funder:** African Research Network for Neglected Tropical Diseases (ARNTD) and United States Agency for International Development (USAID)  
**Deadline and eligibility:** Details on the program eligibility criteria and the review process will be available on the ARNTD website in mid-December 2016.

For more information about BVGH FundFinder, please email [Lisel Koepl](mailto:Lisel.Koepl).
Member Spotlight

The Malaria Consortium published a new report, *Dengue: Falling between the Cracks*, that describes the rise and economic and human impact of dengue fever, and strategies to reduce the burden of the disease globally.

![The Rise of Dengue](image)

**THE RISE OF DENGUE**

- **1960**: 15,000 cases per year
- **2016**: 390,000,000 cases per year

- **9 COUNTRIES REPORTED IT**
  - Philippines
  - Thailand
  - India
  - Malaysia
  - Singapore
  - Vietnam
  - Myanmar
  - Laos
  - Cambodia

- **MORE THAN 100 COUNTRIES ARE Affected**

### 30 MOST ENDEMIC COUNTRIES

**CARIBBEAN**
- Dominican Republic
- Guadeloupe
- Martinique
- Puerto Rico

**CENTRAL AMERICA**
- Costa Rica
- El Salvador
- Guatemala
- Honduras
- Mexico

**SOUTH AMERICA**
- Argentina
- Bolivia
- Brazil
- Colombia
- Ecuador
- French Guiana
- Paraguay
- Peru
- Venezuela

**ASIA**
- Cambodia
- India
- Indonesia
- Laos
- Malaysia
- Myanmar
- Pakistan
- Philippines
- Singapore
- Sri Lanka
- Thailand
- Vietnam

The global incidence of dengue has grown dramatically in recent decades. About 50% of the world's population is now at risk.

Highlighted Contributions

Do you have an asset that you are willing to contribute to another WIPO Re:Search Member to further neglected tropical disease, malaria, or tuberculosis research and development? Email Ujwal Sheth to learn how you can have your asset summarized in the [WIPO Re:Search Database](https://wipo-research-collection.wipo.int/submit) and featured in an upcoming *Snapshot* newsletter.
WIPO Re:Search in the News

BVGH and WIPO’s 2013 article describing WIPO Re:Search was one of the Pharmaceutical Patent Analyst journal’s top cited articles over the past four years. BVGH published an update on WIPO Re:Search, its achievements, alignment to the Sustainable Development Goals (SDGs), and future in a recent issue of the journal.

The International Society for Neglected Tropical Diseases (ISNTD) published an interview with Katy Graef about WIPO Re:Search and its future plans.

Upcoming Global Health Meetings

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb. 19-22</td>
<td>Keystone Symposium: Malaria: From Innovation to Eradication</td>
<td>Kampala, Uganda</td>
<td>Website</td>
</tr>
<tr>
<td>Feb. 28-Mar. 1</td>
<td>7th Annual World Vaccine Summit</td>
<td>Pune, India</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 30-31</td>
<td>18th Drug Design &amp; Development Seminar (DDDS)</td>
<td>Hamburg, Germany</td>
<td>Brochure</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada

Copyright © 2016 BVGH, All rights reserved.

Our mailing address is:
401 Terry Avenue N., Seattle, WA 98109